Immunotherapy for hepatocellular carcinoma - European Medical Journal

Immunotherapy for hepatocellular carcinoma


At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Su Pin Choo, MBBS, MRCP(UK), FAMS, from the National Cancer Centre Singapore, Singapore, discusses the development of immunotherapy for patients with hepatocellular carcinoma (HCC), including early promising clinical data with nivolumab, a programmed cell death-1 (PD-1) antibody.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?